ZYBTZhengye Biotechnology Holding Ltd
Health Care
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect revised up 1.9% for FY 2024
This is the 4th largest revision in ZYBT's history.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
FY 2024
As reported
-8.7MCNYRestated
-8.6MCNY1.9%
Verify against SEC filingsShow
As reported-8.7MCNY
Accepted 2025-07-030001213900-25-061202
Restated-8.6MCNY
Accepted 2026-04-280001213900-26-048584
NetChangeInCash · reported 2 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get an alert the next time ZYBT — or any company on your watchlist — restates a number. Every alert lands with the diff and its source filing.